Cristina Rebordosa (Anton Pottegård)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Left Ventricular

Diabetic Nephropathy

Chronic Obstructive Pulmonary Disease

Muscular Dystrophy

Top Venues

Diabetes, obesity & metabolism

Clinical drug investigation

Neurology and therapy

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes, obesity & metabolism 26 (4) (2024)
Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes, obesity & metabolism (2024)
Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes, obesity & metabolism (2024)
Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes, obesity & metabolism 26 (4) (2024)
Cristina Rebordosa, Reimar W Thomsen, Arlene K Tave, Morten Madsen, Daniel C Beachler, David Martinez, Raquel Garcia-Esteban, Estel Plana, Anita Tormos, Soulmaz Fazeli Farsani, Susana Perez-Gutthann, Manel Pladevall-Vila
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts. Diabetes, obesity & metabolism 26 (4) (2024)
Cristina Rebordosa, Estel Plana, Annalisa Rubino, Jaume Aguado, David Martinez, Alejhandra Lei, Sami Daoud, Nuria Saigi-Morgui, Susanna Perez-Gutthann, Elena Rivero-Ferrer
Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. International journal of chronic obstructive pulmonary disease 17 (2022)
Joan Forns, Elena Dudukina, David Hägg, Péter Szentkúti, Karin Gembert, Estel Plana, Alicia W Gilsenan, Erzsébet Horváth-Puhó, Vera Ehrenstein, Johan Reutfors, Cristina Rebordosa
Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study. Neurology and therapy 11 (4) (2022)
Elena Rivero-Ferrer, Morten Olesen, Estel Plana, Jaume Aguado, Nuria Saigi-Morgui, Annalisa Rubino, Sami Z Daoud, Alejhandra Lei, Susanna Perez-Gutthann, Nina Sahlertz Kristiansen, Nina Sahlertz Kristiansen, Jesper Hallas, Cristina Rebordosa, Cristina Rebordosa
Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clinical drug investigation 42 (4) (2022)
Cristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, Kristina Laugesen, Florian Voss, Jaume Aguado, Ulrich Bothner, Kenneth J Rothman, Kristina Zint, Daniel Mines, Vera Ehrenstein
Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists. Pharmacoepidemiology and drug safety 31 (8) (2022)
Cristina Rebordosa, Eline Houben, Kristina Laugesen, Ulrich Bothner, Jukka Montonen, Jaume Aguado, Jetty A Overbeek, Vera Ehrenstein, Joelle Asmar, Laura Wallace, Alicia W Gilsenan
No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study. Scientific reports 10 (1) (2020)